Maternal use of bupropion and risk for congenital heart defects

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 1, 2010, Pages 52.e1-52.e6

  Alwan, Sura ^a   Reefhuis, Jennita ^b   Botto, Lorenzo D ^c   Rasmussen, Sonja A ^b   Correa, Adolfo ^b   Friedman, Jan M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

birth defects; bupropion exposure; congenital heart defects; pregnancy

Indexed keywords

AMFEBUTAMONE;

ADULT; ARTICLE; BIRTH DEFECT; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIRST TRIMESTER PREGNANCY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 77953915501     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.02.015     Document Type: Article

References (23)

1. Ascher J.A., Cole J.O., Colin J.N., et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56 (1995) 395-401
2. Hurt R.D., Sachs D.P., Glover E.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 (1997) 1195-1202
3. Wisner K.L., Gelenberg A.J., Leonard H., Zarin D., and Frank E. Pharmacologic treatment of depression during pregnancy. JAMA 282 (1999) 1264-1269
4. Tong V.T., England L.J., Dietz P.M., and Asare L.A. Smoking patterns and use of cessation interventions during pregnancy. Am J Prev Med 35 (2008) 327-333
5. Coleman T. Recommendations for the use of pharmacological smoking cessation strategies in pregnant women. CNS Drugs 21 (2007) 983-993
6. GlaxoSmithKline Bupropion Pregnancy Registry. Final report: 1 September 1997 through 31 March 2008. Registry Report. Wilmington, NC, 2008.
7. Bupropion (amfebutamone): caution during pregnancy. Prescrire Int 14 (2005) 225
8. Cole J.A., Modell J.G., Haight B.R., Cosmatos I.S., Stoler J.M., and Walker A.M. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16 (2007) 474-484
9. Yoon P.W., Rasmussen S.A., Lynberg M.C., et al. The National Birth Defects Prevention Study. Public Health Rep 116 suppl (2001) 32-40
10. Botto L.D., Lin A.E., Riehle-Colarusso T., Malik S., and Correa A. National Birth Defects Prevention Study. Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol 79 (2007) 714-727
11. Waller D.K., Shaw G.M., Rasmussen S.A., et al. National Birth Defects Prevention Study. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 161 (2007) 745-750
12. Frieden I.J., Reese V., and Cohen D. PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 132 (1996) 307-311
13. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., and Friedman J.M. National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 256 (2007) 2684-2692
14. Reller M.D., Strickland M.J., Riehle-Colarusso T., Mahle W.T., and Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 153 (2008) 807-813
15. Lewin M.B., McBride K.L., Pignatelli R., et al. Echocardiographic evaluation of asymptomatic parental and sibling cardiovascular anomalies associated with congenital left ventricular outflow tract lesions. Pediatrics 114 (2004) 691-696
16. Chun-Fai-Chan B., Koren G., Fayez I., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 192 (2005) 932-936
17. Tucker W.E. Preclinical toxicology of bupropion: an overview. J Clin Psychiatry 44 (1983) 60-62
18. Diav-Citrin O., Shechtman S., Weinbaum D., et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study. Br J Clin Pharmacol 66 (2008) 695-705
19. Louik C., Lin A.E., Werler M.M., Hernández-Díaz S., and Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356 (2007) 2675-2683
20. Källén B.A., and Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79 (2007) 301-308
21. Berard A., Ramos E., Rey E., Blais L., St-Andre M., and Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80 (2007) 18-27
22. Cole J.A., Ephross S.A., Cosmatos I.S., and Walker A.M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16 (2007) 1075-1085
23. Wogelius P., Norgaard M., Gislum M., et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17 (2006) 701-704